Pemazyre (pemigatinib tablets − Incyte) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has unresectable locally advanced, gross residual, or metastatic disease
• Tumor has fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement as detected by an approved test
• Patient has been previously treated with at least one systemic regimen

Approval duration

1 year